Sotera Health Q2 Preview: Can 5%-6.5% Growth Hold After May's 31.8M-Share Overhang?

Q2 matters because investors want Sotera to look like a steady compounder again

Sotera's next print is less about whether the company can still grow and more about whether the market is willing to own it as a steady compounder again. Investors will judge whether the July 23 earnings-date evidence - together with the company's 5.0% to 6.5% revenue growth and 5.5% to 7.0% EBITDA growth outlook - is enough to shift attention back to operating cadence. That is the baseline management reaffirmed earlier this year. If Q2 stays close to that path, the business case remains intact.

The complication is equity structure. The stock is also carrying a fresh 31,838,253-share overhang from May's secondary offering. That makes the real question less about underlying demand and more about whether shares can trade cleanly while investors absorb a larger share count.

The constructive case is simple: healthcare sterilization, testing, and advisory demand tends to be sticky, and a steady compounder does not need heroic growth. It needs reliable execution and a clear enough path to per-share progress. The risk is that a bigger float muddies that per-share math and keeps value investors from fully re-engaging. If management can show the operating lane is still open and address dilution directly, SHC has a plausible path back to calmer trading. If not, the shares may remain stuck in a "good business, messy equity" pattern.

What a solid Q2 would look like for Sotera

Q1 already set a useful baseline

The best clue is already on the table: in Q1, Sotera delivered 10.0% revenue growth in reported terms, or 6.5% on a constant currency basis, while Adjusted EBITDA increased 10.5%. That does not mean Sotera needs another standout quarter. It means investors need evidence that demand is still moving forward and that profitability is not getting compressed while growth remains moderate. If Q2 shows revenue still growing faster than costs, the market is likely to be more forgiving. If revenue slows sharply and margin commentary weakens, attention will shift back to the bigger share count.

More shares do not automatically mean weaker operations. But weaker operations plus more shares changes the conversation.

Business resilience is already documented

Sotera has already shown this is not a broken model waiting for a miracle. It reported its 20th consecutive year of revenue growth, with 2025 revenue up 5.7% to $1.164 billion and Adjusted EBITDA up 8.2% to $594 million. That is the baseline for a mature, cycle-resistant service business.

A solid Q2 probably will not look dramatic. More likely, it will look dependable:

• revenue growth that keeps the business inside its normal lane
• EBITDA growth that remains healthy relative to revenue
• no fresh sign of softness in the core sterilization, testing, or advisory businesses

If those boxes are checked, bulls can argue the overhang is mainly a trading issue rather than a business issue.

The trading decision after earnings depends on boring, not heroic, execution

Keep the focus on guidance credibility

The cleanest setup is not a hero quarter. It is evidence that the demand engine is still working and that the May secondary offering is being absorbed rather than exposed as a deeper problem. Management needs to stay close to its established 5.0% to 6.5% revenue growth outlook and 5.5% to 7.0% EBITDA growth. If that happens, the stock has a better chance of being viewed again as a steady business rather than a dilution headline.

• Constructive signals: revenue and EBITDA track near the guided bands, cost discipline holds, and guidance language stays firm rather than defensive.
• Warning signs: growth slips meaningfully below the outlook, margin commentary gets less clear, or management sounds uncertain about the cadence ahead.

EO updates could still move sentiment

After the numbers, one of the clearest sentiment levers is how management frames EO regulatory and litigation updates. If those updates sound contained, investors are more likely to look through the bigger share count. If commentary becomes defensive or vague, bears can argue that policy risk is still pressing on the multiple.

For now, the framework is simple: hold or add only if execution stays disciplined and management keeps the operating story credible. A solid quarter and calm commentary should do more for sentiment than a marginal beat paired with weaker guidance language.